Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D Substitution

Next Previous
X
Search
Trial Profile

Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D Substitution

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vincristine (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vitamin D
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Non-Hodgkin's lymphoma; Plasmablastic lymphoma; T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms OPTIMAL>60

    • Most Recent Events

    • 24 Apr 2024 Status changed from active, no longer recruiting to completed.
    • 09 May 2023 Planned End Date changed from 1 May 2024 to 1 May 2025.
    • 09 May 2023 Planned primary completion date changed from 1 Dec 2023 to 1 May 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top